This Article Full Text Full Text (PDF) An erratum has been published Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoshino, Y. Articles by Straus, S. E. Search for Related Content PubMed PubMed Citation Articles by Hoshino, Y. Articles by Straus, S. E.

 Previous Article  |  Next Article 

Journal of Virology, January 2005, p. 410-418, Vol. 79, No. 1
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.1.410-418.2005

Comparative Efficacy and Immunogenicity of Replication-Defective, Recombinant Glycoprotein, and DNA Vaccines for Herpes Simplex Virus 2 Infections in Mice and Guinea Pigs

Yo Hoshino,¹ Sarat K. Dalai,¹ Kening Wang,¹ Lesley Pesnicak,¹ Tsz Y. Lau,¹ David M. Knipe,² Jeffrey I. Cohen,¹ and Stephen E. Straus^1*

Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland,¹ Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts²

Received 11 May 2004/ Accepted 1 September 2004

Many candidate vaccines are effective in animal models of genital herpes simplex virus type 2 (HSV-2) infection. Among them, clinical trials showed moderate protection from genital disease with recombinant HSV-2 glycoprotein D (gD2) in alum-monophosphoryl lipid A adjuvant only in HSV women seronegative for both HSV-1 and HSV-2, encouraging development of additional vaccine options. Therefore, we undertook direct comparative studies of the prophylactic and therapeutic efficacies and immunogenicities of three different classes of candidate vaccines given in four regimens to two species of animals: recombinant gD2, a plasmid expressing gD2, and dl5-29, a replication-defective strain of HSV-2 with the essential genes UL5 and UL29 deleted. Both dl5-29 and gD2 were highly effective in attenuating acute and recurrent disease and reducing latent viral load, and both were superior to the plasmid vaccine alone or the plasmid vaccine followed by one dose of dl5-29. dl5-29 was also effective in treating established infections. Moreover, latent dl5-29 virus could not be detected by PCR in sacral ganglia from guinea pigs vaccinated intravaginally. Finally, dl5-29 was superior to gD2 in inducing higher neutralizing antibody titers and the more rapid accumulation of HSV-2-specific CD8⁺ T cells in trigeminal ganglia after challenge with wild-type virus. Given its efficacy, its defectiveness for latency, and its ability to induce rapid, virus-specific CD8⁺-T-cell responses, the dl5-29 vaccine may be a good candidate for early-phase human trials.

---

* Corresponding author. Mailing address: LCID/NIAID, Building 10, Room 11N228, 10 Center Dr., Bethesda, MD 20892. Phone: (301) 435-6514. Fax: (301) 435-6549. E-mail: strauss{at}mail.nih.gov.

---

Journal of Virology, January 2005, p. 410-418, Vol. 79, No. 1
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.1.410-418.2005

This article has been cited by other articles:

• Burbelo, P. D., Hoshino, Y., Leahy, H., Krogmann, T., Hornung, R. L., Iadarola, M. J., Cohen, J. I. (2009). Serological Diagnosis of Human Herpes Simplex Virus Type 1 and 2 Infections by Luciferase Immunoprecipitation System Assay. CVI 16: 366-371 [Abstract] [Full Text]  
• Brittle, E. E., Wang, F., Lubinski, J. M., Bunte, R. M., Friedman, H. M. (2008). A Replication-Competent, Neuronal Spread-Defective, Live Attenuated Herpes Simplex Virus Type 1 Vaccine. J. Virol. 82: 8431-8441 [Abstract] [Full Text]  
• Hoshino, Y., Pesnicak, L., Cohen, J. I., Straus, S. E. (2007). Rates of Reactivation of Latent Herpes Simplex Virus from Mouse Trigeminal Ganglia Ex Vivo Correlate Directly with Viral Load and Inversely with Number of Infiltrating CD8+ T Cells. J. Virol. 81: 8157-8164 [Abstract] [Full Text]  
• Brockman, M. A., Verschoor, A., Zhu, J., Carroll, M. C., Knipe, D. M. (2006). Optimal Long-Term Humoral Responses to Replication-Defective Herpes Simplex Virus Require CD21/CD35 Complement Receptor Expression on Stromal Cells. J. Virol. 80: 7111-7117 [Abstract] [Full Text]  
• Natuk, R. J., Cooper, D., Guo, M., Calderon, P., Wright, K. J., Nasar, F., Witko, S., Pawlyk, D., Lee, M., DeStefano, J., Tummolo, D., Abramovitz, A. S., Gangolli, S., Kalyan, N., Clarke, D. K., Hendry, R. M., Eldridge, J. H., Udem, S. A., Kowalski, J. (2006). Recombinant Vesicular Stomatitis Virus Vectors Expressing Herpes Simplex Virus Type 2 gD Elicit Robust CD4+ Th1 Immune Responses and Are Protective in Mouse and Guinea Pig Models of Vaginal Challenge. J. Virol. 80: 4447-4457 [Abstract] [Full Text]  
• Tree, J. A., Elmore, M. J., Javed, S., Williams, A., Marsh, P. D. (2006). Development of a Guinea Pig Immune Response-Related Microarray and Its Use To Define the Host Response following Mycobacterium bovis BCG Vaccination. Infect. Immun. 74: 1436-1441 [Abstract] [Full Text]  
• Moser, J. M., Farrell, M. L., Krug, L. T., Upton, J. W., Speck, S. H. (2006). A Gammaherpesvirus 68 Gene 50 Null Mutant Establishes Long-Term Latency in the Lung but Fails To Vaccinate against a Wild-Type Virus Challenge. J. Virol. 80: 1592-1598 [Abstract] [Full Text]  
• Wang, K., Lau, T. Y., Morales, M., Mont, E. K., Straus, S. E. (2005). Laser-Capture Microdissection: Refining Estimates of the Quantity and Distribution of Latent Herpes Simplex Virus 1 and Varicella-Zoster Virus DNA in Human Trigeminal Ganglia at the Single-Cell Level. J. Virol. 79: 14079-14087 [Abstract] [Full Text]